Loading
HPV throat cancer now exceeds cervical cancer in some countries and mostly affects men, who were not vaccinated. Vaccinating men up to 45 could reduce it.
HPV throat cancer now exceeds cervical cancer in some countries and mostly affects men who were never vaccinated, so this idea offers catch-up HPV vaccination to men up to age 45. HPV vaccination reduces oral HPV16 prevalence, oropharyngeal cancer incidence in men is rising, and the vaccine is safe in adults; the causal chain is strong despite the long latency. Oral HPV prevalence would serve as the intermediate endpoint with modelled cancer reduction. The test is prevalence surveys, modelling and cost-effectiveness analysis. Speculative in maturity, it addresses the bottleneck Prevention we already have is not deployed and links to HPV vaccination and head and neck cancer.
School-based vaccination at 12-13 with high uptake nearly abolishes cervical cancer in vaccinated cohorts, even with a vaccine covering only two HPV types. Screening intervals and the future of cervical screening can now be redesigned around vaccination status.
One bottleneck page and 27 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Shares England's HPV programme: cervical cancer down 87% in the first cohort vaccinated at 12-13, Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, HPV & HBV vaccination, Prevention we already have is not deployed.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Prevention we already have is not deployed.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Prevention we already have is not deployed.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Prevention we already have is not deployed.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Prevention we already have is not deployed.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Prevention we already have is not deployed.
Shares Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, HPV & HBV vaccination, Prevention we already have is not deployed, Head and neck squamous cell carcinoma.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Prevention we already have is not deployed.